Clinical trial
Bioequivalence Study of Atazanavir 300 mg Capsule
NCT00393328 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00393328 |
|---|---|
| Title | Bioequivalence Study of Atazanavir 300 mg Capsule |
| Official title | Bioequivalence Study of Atazanavir Single 300 mg Capsule Relative to Two Atazanavir 150 mg Capsules in Healthy Subjects |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir + Ritonavir |
| Enrollment | 46 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Oct 27, 2006 |
| Last update posted | Apr 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: